Deutetrabenazine Patent Expiration
Deutetrabenazine is Used for managing movement disorders associated with neurological conditions. It was first introduced by Teva Branded Pharmaceutical Products R And D Llc
Deutetrabenazine Patents
Given below is the list of patents protecting Deutetrabenazine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Austedo Xr | US11311488 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | Jun 10, 2041 | Teva |
| Austedo Xr | US12589075 | Osmotic Dosage Forms Comprising Deutetrabenazine And Methods Of Use Thereof | Jun 10, 2041 | Teva |
| Austedo Xr | US12599598 | Osmotic Dosage Forms Comprising Deutetrabenazine And Methods Of Use Thereof | Jun 10, 2041 | Teva |
| Austedo |
US11179386 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva Branded Pharm |
| Austedo |
US11813232 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva Branded Pharm |
| Austedo Xr |
US11179386 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva |
| Austedo Xr |
US11813232 (Pediatric) | Analogs of deutetrabenazine, their preparation and use | Sep 15, 2038 | Teva |
| Austedo | US11179386 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva Branded Pharm |
| Austedo | US11813232 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva Branded Pharm |
| Austedo Xr | US11179386 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva |
| Austedo Xr | US11813232 | Analogs of deutetrabenazine, their preparation and use | Mar 15, 2038 | Teva |
| Austedo |
US10959996 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11357772 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11446291 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11564917 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US11648244 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo |
US12016858 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva Branded Pharm |
| Austedo Xr |
US10959996 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11357772 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11446291 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11564917 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US11648244 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo Xr |
US12016858 (Pediatric) | Methods for the treatment of abnormal involuntary movement disorders | Sep 07, 2036 | Teva |
| Austedo | US10959996 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11357772 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11446291 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11564917 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US11648244 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo | US12016858 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva Branded Pharm |
| Austedo Xr | US10959996 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11357772 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11446291 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11564917 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US11648244 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo Xr | US12016858 | Methods for the treatment of abnormal involuntary movement disorders | Mar 07, 2036 | Teva |
| Austedo |
US11666566 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9233959 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9296739 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9550780 (Pediatric) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo |
US9814708 (Pediatric) | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva Branded Pharm |
| Austedo Xr |
US9550780 (Pediatric) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Mar 18, 2034 | Teva |
| Austedo | US11666566 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9233959 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9296739 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo | US9814708 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva Branded Pharm |
| Austedo Xr | US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | Sep 18, 2033 | Teva |
| Austedo |
US8524733 (Pediatric) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Oct 03, 2031 | Teva Branded Pharm |
| Austedo Xr |
US8524733 (Pediatric) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Oct 03, 2031 | Teva |
| Austedo | US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Apr 03, 2031 | Teva Branded Pharm |
| Austedo Xr | US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | Apr 03, 2031 | Teva |
Deutetrabenazine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Deutetrabenazine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Vanderbilt University Medical Center | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Addressing Involuntary Movements in Tardive Dyskinesia | Auspex Pharmaceuticals, Inc. | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |